title: On the in vivo early toxic properties of A-beta 25-35 peptide in the rat hippocampus: involvement of the Receptor-for-Advanced Glycation-End-Products and changes in gene expression.
abstract: Amyloid-beta peptide (Aβ) deposition is assumed to play a pathogenic role in the brain of Alzheimer's disease patients. To date, the precise mechanisms underlying Aβ toxicity are not fully understood. A recent hypothesis suggesting that the Receptor-for-Advanced-Glycation-End-Products (RAGE)-a trans-membrane protein signaling for oxidative stress-is involved in Aβ toxicity is gaining attention. Early Aβ toxicity could indeed help to explain the deleterious events further produced by this molecule in the brain. In this work, we evaluated the pattern of early expression of RAGE in the toxic model induced by Aß₂₅₋₃₅ in rat CA1 region. Intrahippocampal injections of Aβ₂₅₋₃₅ in rats increased the RAGE expression at 24 h post-injection; this event was accompanied by increased components of RAGE downstream signaling in hippocampal cells, such as enhanced expression of the pro-apoptotic factor NF-κB, increased nitric oxide production, LDH leakage, mitochondrial dysfunction, increased TNF-α expression, antioxidant genes down-regulation, and augmented neurodegeneration. Our findings support an active role of RAGE during the early stages of Aβ₂₅₋₃₅ toxicity in the hippocampus.
authors.affiliation: Neurochemistry Laboratory, Division of Neurotoxicology, National Center for Toxicological Research, Jefferson, AR 72079, USA.
authors.forename: Elvis
authors.initials: E
authors.lastname: Cuevas
authors.forename: Susan M
authors.initials: SM
authors.lastname: Lantz
authors.forename: J César
authors.initials: JC
authors.lastname: Tobón-Velasco
authors.forename: Glenn D
authors.initials: GD
authors.lastname: Newport
authors.forename: Qiangen
authors.initials: Q
authors.lastname: Wu
authors.forename: Ashraf
authors.initials: A
authors.lastname: Virmani
authors.forename: Syed F
authors.initials: SF
authors.lastname: Ali
authors.forename: Abel
authors.initials: A
authors.lastname: Santamaría
mesh_terms: D016229:Amyloid beta-Peptides / Q000633:toxicity*; D000818:Animals; D000975:Antioxidants / Q000378:metabolism; D015153:Blotting, Western; D056547:CA1 Region, Hippocampal / Q000187:drug effects* / Q000201:enzymology / Q000378:metabolism / Q000473:pathology; D016923:Cell Death / Q000187:drug effects; D015870:Gene Expression / Q000187:drug effects*; D008297:Male; D008845:Microinjections; D008856:Microscopy, Fluorescence; D008928:Mitochondria / Q000187:drug effects / Q000502:physiology; D009569:Nitric Oxide / Q000096:biosynthesis; D018384:Oxidative Stress / Q000187:drug effects / Q000235:genetics; D010446:Peptide Fragments / Q000633:toxicity*; D051381:Rats; D017207:Rats, Sprague-Dawley; D000067759:Receptor for Advanced Glycation End Products; D011971:Receptors, Immunologic / Q000235:genetics*; D020133:Reverse Transcriptase Polymerase Chain Reaction
chemical_list: D016229:Amyloid beta-Peptides; D000975:Antioxidants; D010446:Peptide Fragments; D000067759:Receptor for Advanced Glycation End Products; D011971:Receptors, Immunologic; C074636:amyloid beta-protein (25-35); D009569:Nitric Oxide